NCT02973802View on ClinicalTrials.gov

ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

February 14, 2018

Study Completion Date

February 14, 2018

Conditions
Graves Disease
Interventions
BIOLOGICAL

ATX-GD-59

Disease specific immune modulating treatment for Graves Disease

Trial Locations (8)

Unknown

Queen Elizabeth Hospital, Birmingham

University Hospital of Wales, Cardiff

Royal Devon and Exeter Hospital, Exeter

Kings College Hospital, London

The Christie, Manchester

Royal Victoria Infirmary, Newcastle

LS9 7TF

St James's University Hospital, Leeds

W12 0HS

Hammersmith Hospital, London

Sponsors
All Listed Sponsors
collaborator

Quintiles, Inc.

INDUSTRY

collaborator

European Commission

OTHER

lead

Apitope International NV

INDUSTRY

NCT02973802 - ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy | Biotech Hunter | Biotech Hunter